SPUTNIK LIGHT
- May 7, 2021
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
SPUTNIK LIGHT
Subject : Science & tech
Context : Russia authorises use of single dose vaccine Sputnik Light
Concept :
- Sovereign wealth fund Russian Direct Investment Fund (RDIF) on Thursday said the move will pave way for the immunisation of a larger number of people in a shorter time frame.
- Sputnik Light is the first component — recombinant human adenovirus serotype number 26 (rAd26) — of Sputnik V vaccine that has been approved by over 60 countries, including India.
- The results of Phase I/II Safety and Immunogenicity Study of Sputnik Light show the vaccine can elicit the development of antigen specific IgG antibodies in 96.9% of volunteers on the 28th day after immunisation.
- Virus-neutralising antibodies developed in 91.67 % of the volunteers on the 28th day post-immunisation. Cellular immune response against the S Protein of SARS-CoV-2 developed in 100% of volunteers.
- Interim results of Phase III clinical study are expected later this month, RDIF said.
- Besides Russia, Sputnik Light is to made in at least 10 other countries where RDIF has formed manufacturing partnerships with 20 producers for Sputnik V.